JEB Technologies is proud to announce that a commercial agreement has been secured with Nottingham University Hospitals NHS Trust (NUH) to manufacture and bring to market a novel paediatric medical device.
The new device, TransiCapTM, has been specially designed as a safe method of monitoring whole gut transit time in paediatric patients who have an indication of constipation. This has the potential to aid with diagnosis, enabling faster and better informed treatment. Developed in conjunction with Professor Luca Marciani and The University of Nottingham, TransiCapTM is supported with funding from the National Institute for Health Research (NIHR) Invention for Innovation (i4i) programme.
Childhood constipation is a common, worldwide problem prevalent in up to 14% of children. It can markedly impair quality of life, as well as having behavioural and social consequences. An objective measure of whole gut transit time can be used to distinguish between different types of constipation to help direct therapy selection and monitor outcomes. However, this is not typically possible in children due to the ionising radiation involved with existing methods, which rely on gamma scintigraphy and x-rays. Management of the condition is instead based largely on symptom reports.
TransiCapTM is a magnetic resonance imaging (MRI) based method of determining whole gut transit time. This is particularly suited to paediatric patients as it is a non-ionising technique. Additionally, it provides high quality, cross-sectional images and a three-dimensional view of the anatomy whilst assessing transit.
A successful clinical investigation of TransiCapTM has recently been completed, with unanimous positive feedback received from young patients and their parents.
It is an exciting time for JEB Technologies as work towards CE marking the device continues in preparation for launch to market.